Discover more from FarmaKology’s Substack
FarmaKology-GSK announces independent Consumer Healthcare company
Curie Therapeutics is a fully integrated next generation radiopharmaceutical company that brings together experts in ligand discovery, radiochemistry, radiobiology and oncology translational and clinical research in order to build a pipeline across a range of solid tumor types. Our mission at Curie is to discover and develop safe, effective, and highly targeted radiopharmaceuticals.
Honeywell Teams With AstraZeneca To Develop Next-Generation Respiratory Inhalers That Use Near-Zero Global Warming Potential Propellant
Honeywell today announced a commercial partnership with AstraZeneca to develop and bring to market next-generation respiratory inhalers that use near-zero global warming potential (GWP) propellants to treat asthma and chronic obstructive pulmonary disease (COPD).As many as 384 million people suffer from COPD, a progressive respiratory disease, and 339 million children and adults suffer from asthma. Many of these patients are currently treated using pressurized metered dose inhalers (pMDIs) that can contribute to the global carbon footprint of respiratory care.
Secarna Pharmaceuticals' Partner Denali Therapeutics Exercises Option for LNAplusTM Antisense Oligonucleotide Development Program in Neurodegeneration
Secarna Pharmaceuticals GmbH & Co. KG , a biopharmaceutical company focusing on the discovery and development of next-generation antisense oligonucleotide therapies to address challenging or previously undruggable targets, announced that Denali Therapeutics Inc. has exercised its option to in-license an ASO program generated by Secarna through its proprietary drug discovery and development platform, LNAplusTM. This program is part of the Research Collaboration and Option Agreement between the two companies and is the first project for which Denali has exercised an option.
Sema4, an AI-driven genomic and clinical data intelligence platform company, and BioSymetrics, a phenomics-driven drug discovery company, today announced a strategic partnership to accelerate the advancement of new medicines for patients and pharmaceutical companies. The partnership will leverage Centrellis®, Sema4’s proprietary health intelligence platform, and Elion, BioSymetrics’ phenotypic drug discovery platform, to discover new treatments initially in cardiovascular, rare and neurological diseases. Together, the companies will launch up to 10 new therapeutic programs in areas of high unmet need where multi-omics offers a differentiated approach to discovering drugs.
Skymount Medical Receives UK MHRA Approval to Test New Treatment in Patients with Mild to Moderate COVID-19
Skymount Medical, a drug discovery company using an artificial intelligence (AI) platform developed by Louisiana State University researchers to repurpose and build new drugs, announced today that it has received approval from the United Kingdom’s Medicines and Healthcare products Regulatory Agency to conduct a human clinical trial of its novel oral therapeutic for patients with mild to moderate COVID-19. The study will be a double-blind intervention comparing a two-drug combination and a single antiviral drug to a placebo. It will determine the impact these therapies will have on the length and severity of COVID-19 symptoms.
GlaxoSmithKline plc today announced that the new company, to result from the proposed demerger of Consumer Healthcare from GSK in mid-2022, will be called Haleon. Haleon (pronounced "Hay-Lee-On") is inspired by the merging of the words 'Hale', which is an old English word that means 'in good health' and Leon, which is associated with the word 'strength'. The new brand identity was developed with input from employees, healthcare practitioners and consumers and will be deployed in more than 100 markets around the world where the business operates.